Stoke Therapeutics (STOK) Total Current Liabilities (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Total Current Liabilities of $40.8 million for Q1 2026, down 8.68% year-over-year from $44.7 million in Q1 2025, and down 29.49% quarter-over-quarter from $57.9 million in Q4 2025.
Stoke Therapeutics (STOK) Total Current Liabilities (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $40.8 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 8.68% year-over-year to $40.8 million; the TTM figure through Mar 2026 stood at $40.8 million (down 8.68% YoY), while the FY2025 annual figure was $57.9 million, up 44.49% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $40.8 million, down from $57.9 million in the prior quarter.
- The five-year high for Total Current Liabilities was $57.9 million in Q4 2025, with the low at $21.8 million in Q2 2023.
- The 5-year median for Total Current Liabilities is $35.6 million (2024), against an average of $36.1 million.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 274.88% in 2022, then fell 21.02% in 2023.
- Stoke Therapeutics' Total Current Liabilities stood at $31.4 million in 2022, then fell by 1.83% to $30.8 million in 2023, then gained by 29.97% to $40.1 million in 2024, then soared by 44.49% to $57.9 million in 2025, then dropped by 29.49% to $40.8 million in 2026.
- Business Quant data shows STOK's Total Current Liabilities at $40.8 million in Q1 2026, $57.9 million in Q4 2025, and $41.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 41.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.93 Mn |
| Mar 31, 2026 | 40.81 Mn |
| Dec 31, 2025 | 57.88 Mn |
| Sep 30, 2025 | 41.73 Mn |
| Jun 30, 2025 | 38.68 Mn |
| Mar 31, 2025 | 44.69 Mn |
| Dec 31, 2024 | 40.06 Mn |
| Sep 30, 2024 | 49.87 Mn |
| Jun 30, 2024 | 44.50 Mn |
| Mar 31, 2024 | 35.59 Mn |
| Dec 31, 2023 | 30.82 Mn |
| Sep 30, 2023 | 25.20 Mn |
| Jun 30, 2023 | 21.84 Mn |
| Mar 31, 2023 | 31.53 Mn |
| Dec 31, 2022 | 31.39 Mn |
| Sep 30, 2022 | 28.80 Mn |
| Jun 30, 2022 | 27.65 Mn |
| Mar 31, 2022 | 22.91 Mn |
| Dec 31, 2021 | 17.14 Mn |
| Sep 30, 2021 | 11.88 Mn |